ADMA Biologics, Inc. Return on Equity (ROE) for the Trailing 12 Months (TTM) ending March 31, 2025: 72.39%

ADMA Biologics, Inc. Return on Equity (ROE) is 72.39% for the Trailing 12 Months (TTM) ending March 31, 2025, a -3,015.53% change year over year. Return on equity measures profit against shareholder equity; higher ROE indicates superior profitability and value creation.
  • ADMA Biologics, Inc. Return on Equity (ROE) for the Trailing 12 Months (TTM) ending March 31, 2024 was -2.48%, a -94.63% change year over year.
  • ADMA Biologics, Inc. Return on Equity (ROE) for the Trailing 12 Months (TTM) ending March 31, 2023 was -46.25%, a -36.95% change year over year.
  • ADMA Biologics, Inc. Return on Equity (ROE) for the Trailing 12 Months (TTM) ending March 31, 2022 was -73.34%, a -14.54% change year over year.
  • ADMA Biologics, Inc. Return on Equity (ROE) for the Trailing 12 Months (TTM) ending March 31, 2021 was -85.82%, a -19.01% change year over year.
Key Data
Date Return on Equity (ROE) Return on Assets (ROA) Revenue Per Share Free Cash Flow Per Share